Abstract TH184: Demographic Variation in Cardiorenal Complications Among Patients With Resistant Hypertension and Heart Failure With Preserved Ejection Fraction
Abstract
Background: Resistant hypertension and heart failure with preserved ejection fraction (HFpEF) frequently coexist, yet the long-term burden of downstream cardiorenal complications, and whether that burden is equally distributed across demographic groups, remains poorly characterized. Decade-long real-world data are needed to define the natural history of this phenotype and identify populations warranting closer surveillance. Hypothesis: Among adults with resistant hypertension and HFpEF, incidence of progression to systolic heart failure, end-stage renal disease, atrial fibrillation, cardiogenic shock, and defibrillator implantation varies substantially by race, sex, and age. Methods: Using the TriNetX Global Collaborative Network (176 healthcare organizations, approximately 120 million patients), we identified 12,401 adults aged 18 years or older with resistant hypertension (ICD-10 I1A.0) and HFpEF, free of prior systolic heart failure (I50.20-I50.23) at baseline. Five events of interest were assessed over an 11-year window from January 2015 to January 2026: progression to systolic heart failure, defibrillator implantation, cardiogenic shock, end-stage renal disease, and incident atrial fibrillation. Incidence proportion and prevalence were calculated overall and stratified by age, sex, race, and ethnicity. Results: Progression to systolic heart failure occurred in 26.4% of patients, atrial fibrillation in 29.0%, end-stage renal disease in 20.7%, defibrillator implantation in 2.7%, and cardiogenic shock in 2.7%. Substantial racial disparities emerged for end-stage renal disease, ranging from 15.4% in White patients to 25.2% in Black patients, 33.2% in Asian patients, and 36.9% in Native Hawaiian or Pacific Islander patients. A similar gradient was observed for systolic heart failure progression, ranging from 24.5% in White to 32.0% in Other Race patients[RT1] . Male sex was associated with higher incidence across all outcomes, most notably defibrillator implantation, roughly 54% more frequent in men (3.3% versus 2.1%). Atrial fibrillation incidence more than doubled with age, from 21.5% at 45-49 years to 47.3% at 75-79 years, while end-stage renal disease incidence paradoxically declined with advancing age. Conclusions: In a large real-world cohort with resistant hypertension and HFpEF, nearly one in three patients progressed to systolic heart failure or developed atrial fibrillation over a decade, with end-stage renal disease disproportionately affecting Black, Asian, Native Hawaiian, and Pacific Islander patients. These findings identify resistant hypertension with HFpEF as a high-burden phenotype with pronounced racial disparities in renal outcomes, supporting targeted surveillance and earlier nephroprotective intervention in disproportionately affected populations.